
CURE.

IMMUNITY.
RECRUITED.

KAHR BIO

DSP107 - Turning the Promise of Immunotherapy Into a Reality for MSS CRC Patients



Yaron Pereg, CEO | December 2024 | CRC Summit

The Immunotherapy Revolution

2014
First FDA
approval



>20
Approved
indications
since

Demonstrated
curative
potential

50% oncology
market
(by 2030)

IMMUNITY.
RECRUITED.

Immunotherapy Ineffective in MSS CRC

High CD47 expression inactivates innate immunity

Low mutational burden maintains tumor invisible



Immune suppressive TME

Activated angiogenesis fuels immune tolerance

Cold immune composition - Low in T cells High in TAMs

IMMUNITY. RECRUITED.

DSP107 Simultaneously Activates Innate and Adaptive Immunity

1. Cancer selective binding to overexpressed CD47 on tumor cells (red blood cells unaffected)
2. Reactivation of innate immunity through macrophage mediated phagocytosis
3. Conditional 4-1BB-mediated T cell engagement and activation

4-1BB is a costimulatory receptor that when activated enhances T-cell activation

4-1BB Ligands



- Cytolytic T cell activation
- T cell Proliferation
- Checkpoint inhibition
- TME modulation

SIRPα for CD47 Blockade

CD47 overexpressed on cancer cells, delivers “don’t eat me” signal inhibiting macrophage activity

IMMUNITY. RECRUITED.

DSP107 Modulates the Immunosuppressive TME



CD47 overexpressed delivers **"don't eat me"** signal inhibiting innate immunity

DSP107 binding anchors 4-1BB ligands to **activate T cells**

Anti PD(L)1 agent further **unleashes T cell activity**

DSP107 activates innate immunity by blocking CD47

Innate immune cells **present cancer antigens**, amplifying adaptive immune response

IMMUNITY. RECRUITED.

DSP107 Promising Phase 2 Data in MSS CRC

- DSP107 monotherapy (n=17) and combination with Atezolizumab (n=21) tested in 3L MSS CRC patients[1]
- Excellent and differentiated safety profile demonstrated in more than 110 solid tumor patients
- 62% disease control (including 1 CR and 1 PR) in patient population that included >70% patients with liver metastases
- Median OS not reached yet, however, DSP107 + Atezolizumab already demonstrates superior survival to the best SOC
- DSP107 + Atezolizumab demonstrate the same level of activity and survival benefit in patients with liver metastases



13-018 MSS CRC patient

KRAS mutated; with liver and lung metastases



- 46 year old male patient with Adenocarcinoma of sigmoid colon
- Previous lines include: XELOX, XELOX + Bev, FOLFIRI + Bev, JAB-3312 + binemitinib, Lonsurf
- Achieved 18 months PR (-86%), survival ongoing >2 years

IMMUNITY. RECRUITED.

[1]Anwaar Saeed et. al., ESMO GI 2024

Mechanism for DSP107 TME Modulation in MSS CRC

- CD47 protein is elevated in CRC liver metastases post FOLFOX and correlates with proportion of phagocytic macrophages[1]
- CD47 overexpression enables DSP107 binding, anchoring 4-1BB ligands to the tumor surface, thereby providing a co-stimulation activation signal to T-cells in the TME[2]

CD47 expression increases post FOLFOX



DSP107 effect on TME immune cell composition



[1]Yi Zhang et. al., SITC 2024

[2]Jason Luke et. al., ASCO 2022

IMMUNITY. RECRUITED.

Expanding Our Ambition - The Synergistic Trio

Addition of VEGF inhibitor could further modulate the TME to be more favorable for DSP107 + Atezolizumab therapy

Mechanism of Action Rationale

- CD47-high tumors have activated angiogenesis and higher expression of PD-1 and PD-L1 [1]
- VEGF-A has a fundamental role in driving T cell exhaustion in the TME in MSS CRC [2]

- **Anti-VEGF** will increase T cell infiltration reshaping the TME to be more immunogenic
- **DSP107** will activate macrophages and prime T cells
- **Atezolizumab** will unleash T cell cytotoxicity
- Tumor killing will increase antigen presentation, amplifying the immune response



[1]Arai H et al; Journal for ImmunoTherapy of Cancer 2024;12:e010326
[2]Kim et al., Sci. Im munol. 2019

IMMUNITY. RECRUITED.

Vision For the Future - Redefining MSS CRC Treatment

Turning the promise of immunotherapy into a reality for MSS CRC patients

- DSP107 combined with Atezolizumab and an anti-VEGF may further extend survival and achieve curative outcomes
- KAHR plans to test the addition of Bevacizumab to DSP107 + Atezolizumab in a randomized, controlled phase II study
- Our Mission - Transforming metastatic MSS CRC into a curable cancer

107_003 Phase II - Randomized Controlled Efficacy Trial

Indication:

3L MSS CRC (n~100)

- With prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; VEGF inhibitor; EGFR inhibitor if RAS wild type
- Patients with or without Liver metastases

Treatment arms:

1. DSP107 + Atezo + Bev
2. Lonsurf + Bev

Objectives:

- Efficacy
  - Primary: median OS
  - Secondary: 12 months OS rate, PFS, ORR, DCR

Planned study design, subject to fine tuning based on regulatory and bio-statistician input

KAHR IMMUNITY. RECRUITED.

Leadership Team

Aron Knickerbocker, MBA

Board Chairman

aulos
Genentech
FivePrime
Bristol Myers Squibb
AMGEN

Yaron Pereg, PhD

Chief Executive Officer

Genentech
BIOLINERX
CELLECT

Tomer Cohen, MBA

Chief Financial Officer

LOCUST WALK
BARCLAYS
Goldman Sachs

Adam Foley-Comer, MD

Chief Medical Officer

Roche
BIOLINERX
QUINTILES
IMMUNE Pharmaceuticals

Ayelet Chajut, PhD

Chief Technology Officer

Pluristem
ROSETTA GENOMICS
Quark Pharmaceuticals
compugen

IMMUNITY. RECRUITED.

Clinical Advisors and Board of Directors

CRC Clinical Advisory Board

Andres Cervantes, M.D.
Head of the Department of Medical Oncology, Valencia University; ESMO President

Aparna Parikh, M.D.
Medical Director, Colorectal Cancer Center, Mass General Cancer Center, Boston

George Thomas, M.D.
Deputy Director of the GI Oncology Program at the University of Florida

Anwaar Saeed, M.D.
Chief, Gastrointestinal Medical Oncology at The University of Pittsburgh

Babar Bashir, M.D.
Assistant Prof. of Medical Oncology & Scientific Co-Director, Early Drug Development at The Sidney Kimmel Cancer Center Jefferson Health

Mark Tykocinski, MD
KAHR technology inventor; BOD Observer; Jefferson Thomas University

Board of Directors

Aron Knickerbocker
President & CEO of Aulos Bioscience, co-founder of RayzeBio; 25+ years as a leader in biotech

aulos

Thomas Eldered
Chairman and owner of Flerie Invest AB; 25+ yrs in biotech and life sciences

FLERIE INVEST

Todd Sone
General Partner at aMoon; 20+ yrs in healthcare investments

aMoon ACCELERATING CURE

Merav Kaye
Investment manager in Consensus Business Group; 7+ yrs in business development

Consensus Business Group

Jennifer Minai-Azary
CFO of Context Therapeutics. 20+ yrs of finance experience

context therapeutics

Eyal Lifschitz
General Partner and Co-Founder of Peregrine Ventures; 20+ yrs managing biotech companies

PEREGRINE VENTURES

Yaron Pereg
KAHR CEO since 2017; 15+ years as a leader in biotech

KAHR IMMUNITY. RECRUITED.